Ascendis Pharma A/S (BVMF:A1SN34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 78.65B |
| Revenue (ttm) | 6.20B +113.4% |
| Net Income | 4.39B |
| EPS | 69.34 |
| Shares Out | n/a |
| PE Ratio | 17.91 |
| Forward PE | 43.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 266 |
| Open | 80.00 |
| Previous Close | 79.78 |
| Day's Range | 77.25 - 80.00 |
| 52-Week Range | 70.00 - 94.05 |
| Beta | 0.49 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About Ascendis Pharma
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]
Financial Performance
In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.
Financial numbers in EUR Financial StatementsNews
Ascendis Pharma falls -12.8%
Ascendis Pharma (ASND) is down -12.8%, or -$33.92 to $231.00.
Ascendis Pharma falls -12.1%
Ascendis Pharma (ASND) is down -12.1%, or -$32.14 to $232.78.
Ascendis Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Announced a $400 million share buyback and reaffirmed Vision 2030 goals of €5 billion in revenue, driven by three approved products and global expansion. Strong product launches, robust pipeline, and regained cardiometabolic rights support long-term growth, with no plans for new capital raises.
Ascendis Pharma downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded Ascendis Pharma (ASND) to Outperform from Strong Buy with an unchanged price target of $287 after the company announced it will regain the rights on the TransCon…
Ascendis Pharma to regain rights to TransCon technology-based products
Ascendis Pharma (ASND) announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, includ...
Ascendis Pharma announces $400M share repurchase plan
Ascendis Pharma (ASND) announced that its Board of Directors has authorized the company to repurchase up to $400M of the company’s ordinary shares.
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple program...
Ascendis Announces Planned $400 Million Share Repurchase Program
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of th...
Ascendis Pharma announces data from reACHin Trial
Ascendis Pharma (ASND) announced Week 52 data from the open-label sentinel cohort portion of the reACHin Trial showing that treatment with once-weekly TransCon CNP provided stabilization or improvemen...
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual...
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, ...
Ascendis Pharma price target raised to $312 from $304 at Oppenheimer
Oppenheimer raised the firm’s price target on Ascendis Pharma to $312 from $304 and keeps an Outperform rating on the shares. The firm has revised its Ascendis (ASND) model to…
Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley
Morgan Stanley analyst Maxwell Skor lowered the firm’s price target on Ascendis Pharma (ASND) to $273 from $275 and keeps an Overweight rating on the shares after the company and…
H.C. Wainwright trims Ascendis target, says litigation overhang removed
H.C. Wainwright lowered the firm’s price target on Ascendis Pharma (ASND) to $344 from $345 and keeps a Buy rating on the shares. The Yuviwel royalty settlement with BioMarin (BMRN)…
BioMarin price target raised to $60 from $59 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BioMarin (BMRN) to $60 from $59 and keeps a Neutral rating on the shares after Ascendis Pharma (ASND) agreed to pay the…
Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN)
Ascendis Pharma stock rallied 7% on Monday after the company reached a global settlement and license deal with BioMarin Pharmaceutical.
Ascendis Pharma rises 8.0%
Ascendis Pharma (ASND) is up 8.0%, or $19.81 to $267.72.
Ascendis Pharma price target lowered to $304 from $306 at BofA
BofA lowered the firm’s price target on Ascendis Pharma (ASND) to $304 from $306 and keeps a Buy rating on the shares after the company a binding term sheet with…
Ascendis Pharma price target lowered to $330 from $333 at Jefferies
Jefferies lowered the firm’s price target on Ascendis Pharma (ASND) to $330 from $333 and keeps a Buy rating on the shares after the company settled its dispute with BioMarin…
Ascendis Pharma price target lowered to $326 from $328 at Stifel
Stifel lowered the firm’s price target on Ascendis Pharma (ASND) to $326 from $328 and keeps a Buy rating on the shares after the company settled its dispute with BioMarin…
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with Bi...
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasi...
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injecti...
Ascendis Pharma Earnings Call Transcript: Q2 2026
Q2 2026 saw product revenue more than double year-over-year to €315 million, driven by robust demand for YORVIPATH, SKYTROFA, and the U.S. launch of YUVIWEL. The company projects over €500 million in operating cash flow for 2026 and remains on track for its €5 billion 2030 revenue goal.